Analysis of Tear Fluid Cystatin C as Biomarkers in Patients with Primary Ocular Tumors
Keywords:
Benign Ocular Tumor, Malignant Ocular Tumor, Cystatin C, Tear FluidAbstract
Introduction: Cystatin C is known to play a role in tumor development and is expected to be used as a biomarker in eye tumors.
Purpose: To analyze levels of tear fluid cystatin C as biomarkers of primary ocular tumors.
Materials and Methods: This study was an analytical observational study with a case-control design. A total of 25 subjects with eye tumors in the study group and 25 subjects without eye tumors in the control group were included. Sampling was conducted from April 2022-July 2022 at the Eye Polyclinic of the Reconstructive Ocuplasty and Oncology division. The Mann-Whitney test was used with a significance level of 5%.
Results: There was a significant difference in the tear fluid Cystatin C level between subjects with eye tumors and without eye tumors (p<0.001), with the mean tear fluid Cystatin C in the eye tumor group of 1.43 mg/dL. However, there was a significant difference in the level of tear fluid Cystatin C between the groups of subjects with malignant eye tumors and benign eye tumors (p=0.042).
Conclusion: There was a significant relationship between tear fluid cystatin C levels and eye tumors (p < 0.001).
Downloads
Published
Issue
Section
License
Terms and conditions of Creative Commons Attribution 4.0 International License apply to all published manuscripts. This Journal is licensed under a Creative Commons Attribution 4.0 International License. This licence allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs and other platforms by providing appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
A competing interest exists when professional judgment concerning the validity of research is influenced by a secondary interest, such as financial gain. We require that our authors reveal all possible conflicts of interest in their submitted manuscripts.
The Editor reserves the right to shorten and adjust texts. Significant changes in the text will be agreed with the Authors.